Hematology (Blood Disorders)

At Nemours, we promise to do whatever it takes to treat children as we would our own. When your child comes to Nemours, we know you’re placing your trust in us. This trust and our dedication to improving the health of your child is what inspires us to provide exceptional care and the most satisfying experience possible.

Dr. Kolb Appointed to Children's Oncology Group Scientific Council

Anders “Andy” Kolb, MD

Anders “Andy” Kolb, MD, Director of the Center for Cancer and Blood Disorders at Nemours/Alfred I. duPont Hospital for Children, has been appointed to the Children’s Oncology Group (COG) Scientific Council.

The COG is a clinical trials group supported by the National Cancer Institute and dedicated to childhood and adolescent cancer research. With cancer centers in North America, Australia, New Zealand, and Europe, the COG consists of more than 7,500 experts on childhood cancer.
The prestigious Scientific Council oversees the COG’s scientific direction and assures the quality and merit of the studies it pursues. As a council member, Dr. Kolb will review concepts for studies to determine scientific merit and to make sure that the proposed studies adhere to the scientific agenda of the COG and its committees. He will also participate in deliberations, act as a primary reviewer on some concepts and advise on major amendments to treatment protocols.

Dr. Kolb currently serves on the COG Bone Tumor Disease Committee and this year was nominated as the Young Investigator Committee Liaison for the Biopathology/Translational Discipline. As a young investigator liaison, Dr. Kolb helps to pair national and international mentors with mentees to promote the research careers of young investigators. In addition, he serves in leadership roles on three specific COG clinicial trials.

Dr. Kolb said, "The Children's Oncology Group is an international leader in pediatric cancer research, and it is a great privilege to serve on the Scientific Council. This is a wonderful opportunity for Nemours to become an active participant in the national pediatric cancer research agenda."